Soligenix induces warrant exercise for up to $4.2M, issues new warrants at 150% coverage

SOLIGENIX, INC.

Up to 703,125 existing warrants exercised at $6.00/share; gross proceeds up to ~$4.2M.
For each exercised warrant, company issues new warrant to purchase 150% of shares, exercisable at $6.00, 5-year term.
New warrants unregistered; company to file S-1 resale registration by July 25, 2024.
A.G.P. receives 6% fee of gross proceeds; net proceeds for clinical development and working capital.
Exhibit warns of potential Nasdaq delisting risk if compliance not regained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.